BioCentury | Oct 12, 2017
Preclinical News

Team describes MECP2 gene therapy approach for Rett syndrome

In a paper published in Nature , researchers at the University of Edinburgh and colleagues showed that adeno-associated virus (AAV) delivery of a shortened version of the methyl CpG binding protein 2 ( MECP2 ; RTT) gene...
BioCentury | Jan 8, 2015
Distillery Therapeutics

Therapeutics: Nidogen-1 (NID1); NID2

...help prevent tetanus neurotoxin-induced paralysis during Clostridium tetani infection. In mouse motor neurons, full-length recombinant NID1...
...short nidogen peptides blocked the interaction and prevented toxin internalization. In mice, administration of the NID1...
...symptoms in wild-type mice. Next steps include developing stable analogs of the nidogen peptides. TARGET/MARKER/PATHWAY: Nidogen-1 (NID1)...
BioCentury | Jul 15, 2013
Regulation

Coding for utility

New, tougher requirements for obtaining Medicare coverage are increasing the cost and time needed to get laboratory-developed molecular diagnostics onto the market and decreasing the certainty that they will be covered. Empowered by a new...
BioCentury | Jun 3, 2013
Company News

Predictive Biosciences diagnostic news

Predictive Biosciences is ceasing operations and laying off all 91 employees after CMS contractor CGS Administrators LLC decided to deny coverage for the company's bladder cancer diagnostics. CEO Pierre Cassigneul told BioCentury that the company...
BioCentury | May 21, 2012
Company News

MDxHealth, Predictive Biosciences sales and marketing update

MDxHealth said in its 1Q12 earnings that partner Predictive launched its CertNDx Bladder Cancer Assay. The assay is a non-invasive diagnostic urine test combining matrix metalloproteinase 2 (MMP2) , fibroblast growth factor (FGF) receptor 3 ( FGFR3...
BioCentury | Jan 31, 2011
Clinical News

Bladder Cancer Assay diagnostic data

A trial in urine samples from patients with bladder cancer and healthy controls showed that Predictive's CertNDx Bladder Cancer Assay using MMP2, FGFR3, TWIST1 and NID2 biomarkers had 94% specificity and a 99.5% negative predictive...
BioCentury | Feb 22, 1999
Tools & Techniques

Inflection points

As news watchers come to realize, seemingly independent events have a way of piling up on themselves and pushing other topics into the background. With the stars thus aligned, it becomes impossible to ignore the...
BioCentury | Dec 14, 1998
Tools & Techniques

Diabetes Pipeline

Diabetes Pipeline Company Product Product type Therapeutic focus Status Ergo Science (ERGO) Ergoset bromocriptine dopamine D2 agonist Regulate glucose metabolism NDA nonapprovable Novo Nordisk NovoRapid short-acting insulin analog Regulate glucose metabolism NDA, MAA submitted SmithKline...
Items per page:
1 - 8 of 8